Poor tolerability of thalidomide in end-stage oesophageal cancer

European Journal of Cancer Care

Volumn 20, Issue 5, 2011, Pages 593-600

  Wilkes, E A ^a,b   Selby, A L ^b   Cole, A T ^a   Freeman, J G ^a   Rennie, M J ^b   Khan, Z H ^c  

^a DERBY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c YEOVIL DISTRICT HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cachexia; Cancer; Nutrition; Oesophagus; Thalidomide; Weight

Indexed keywords

THALIDOMIDE;

AGED; ARTICLE; CACHEXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESOPHAGUS TUMOR; ETHNOLOGY; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; CACHEXIA; DOUBLE-BLIND METHOD; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; SURVIVAL ANALYSIS; THALIDOMIDE; WEIGHT GAIN;

EID: 79960848659     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2011.01255.x     Document Type: Article

References (21)

1. Bennett C.L., Angelotta C., Yarnold P.R., Evens A.M., Zonder J.A., Raisch D.W. & Richardson P. (2006) Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA: The Journal of the American Medical Association 296, 2558-2560.
2. Bruera E., Macmillan K., Kuehn N., Hanson J. & MacDonald R.N. (1990) A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 66, 1279-1282.
3. Clark T.E., Edom N., Larson J. & Lindsey L.J. (2001) Thalomid (thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Safety 24, 87-117.
4. DeWys W.D., Begg C., Lavin P.T., Band P.R., Bennett J.M., Bertino J.R., Cohen M.H., Douglass H.O., Jr, Engstrom P.F., Ezdinli E.Z., Horton J., Johnson G.J., Moertel C.G., Oken M.M., Perlia C., Rosenbaum C., Silverstein M.N., Skeel R.T., Sponzo R.W. & Tormey D.C. (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. The American Journal of Medicine 69, 491-497.
5. Dimopoulos M.A. & Eleutherakis-Papaiakovou V. (2004) Adverse effects of thalidomide administration in patients with neoplastic diseases. The American Journal of Medicine 117, 508-515.
6. Emery P.W., Edwards R.H., Rennie M.J., Souhami R.L. & Halliday D. (1984) Protein synthesis in muscle measured in vivo in cachectic patients with cancer. British Medical Journal (Clinical Research Ed.) 289, 584-586.
7. Feliu J., Gonzalez-Baron M., Berrocal A., Artal A., Ordonez A., Garrido P., Zamora P., Garcia de Paredes M.L. & Montero J.M. (1992) Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo-controlled study. American Journal of Clinical Oncology 15, 436-440.
8. Fellows I.W. & Macdonald I.A. (1985) An automated method for the measurement of oxygen consumption and carbon dioxide excretion in man. Clinical Physics and Physiological Measurement 6, 349-355.
9. Fullerton P.M. & O'Sullivan D.J. (1968) Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study. Journal of Neurology, Neurosurgery, and Psychiatry 31, 543-551.
10. Gordon J.N., Trebble T.M., Ellis R.D., Duncan H.D., Johns T. & Goggin P.M. (2005) Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54, 540-545.
11. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M. & Melton L.J., III (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Archives of Internal Medicine 160, 809-815.
12. Inui A. (2002) Cancer anorexia-cachexia syndrome: current issues in research and management. CA: A Cancer Journal for Clinicians 52, 72-91.
13. Kaplan G., Thomas S., Fierer D.S., Mulligan K., Haslett P.A., Fessel W.J., Smith L.G., Kook K.A., Stirling D. & Schambelan M. (2000) Thalidomide for the treatment of AIDS-associated wasting. AIDS Research and Human Retroviruses 16, 1345-1355.
14. Keifer J.A., Guttridge D.C., Ashburner B.P. & Baldwin A.S., Jr (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. The Journal of Biological Chemistry 276, 22382-22387.
15. Khan Z.H., Simpson E.J., Cole A.T., Holt M., MacDonald I., Pye D., Austin A. & Freeman J.G. (2003) Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Alimentary Pharmacology and Therapeutics 17, 677-682.
16. Oster M.H., Enders S.R., Samuels S.J., Cone L.A., Hooton T.M., Browder H.P. & Flynn N.M. (1994) Megestrol acetate in patients with AIDS and cachexia. Annals of Internal Medicine 121, 400-408.
17. Palumbo A., Rajkumar S.V., Dimopoulos M.A., Richardson P.G., San M.J., Barlogie B., Harousseau J., Zonder J.A., Cavo M., Zangari M., Attal M., Belch A., Knop S., Joshua D., Sezer O., Ludwig H., Vesole D., Blade J., Kyle R., Westin J., Weber D., Bringhen S., Niesvizky R., Waage A., von Lilienfeld-Toal M., Lonial S., Morgan G.J., Orlowski R.Z., Shimizu K., Anderson K.C., Boccadoro M., Durie B.G., Sonneveld P. & Hussein M.A. (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22, 414-423.
18. Powell R.J. & Gardner-Medwin J.M. (1994) Guideline for the clinical use and dispensing of thalidomide. Postgraduate Medical Journal 70, 901-904.
19. Rennie M.J., Atherton P., Patel R., Larvin M., Liptrot S., Lund J., Rankin D., Selby A., Smith K. & Wilkes E. (2007) Patients with colorectal cancer show anabolic resistance of muscle signalling and protein turnover to amino acid availability which is resolved after curative resection. NCRN Abstract. Available at: (accessed on 29 March 2011).
20. Springer J., Filippatos G., Akashi Y.J. & Anker S.D. (2006) Prognosis and therapy approaches of cardiac cachexia. Current Opinion in Cardiology 21, 229-233.
21. Weisberg J., Wanger J., Olson J., Streit B., Fogarty C., Martin T. & Casaburi R. (2002) Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest 121, 1070-1078.